Astellas Pharma

Money Moves

Holds exclusive option to license DAX-044 worldwide

A Melbourne drug developer founded by two researchers and funded largely from their own pockets has signed one of the biggest preclinical drug deals to come out of Australia. Japanese drugmaker Astellas now holds the exclusive option to license Audax Biosciences' lead cancer therapy worldwide, a package worth up to $1.34 billion before royalties.

Updated 2 hours ago

Rule Changes

Markets fezolinetant (Veozah), one of the two nonhormonal drugs in the new guideline

The American College of Obstetricians and Gynecologists published its first menopause guideline update since 2014 on October 15. It makes hormone therapy the first choice for women under 60 or within 10 years of their last period, and it says the evidence does not support herbal or soy-based supplements, which the FDA does not regulate.

Updated 2 days ago

New Capabilities

Maker of the first approved CLDN18.2 drug

Advanced gastric cancer that returns after treatment usually kills within about six months. On June 4, 2026, Chinese biotech Innovent Biologics said its drug had slowed that clock in a late-stage trial.

Updated Jun 4